Microcap Ledger Prokidney Corp. $PROK
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Winston-Salem, NC
- Fiscal year end
- December 31
What the company doesAI summary of filing
ProKidney Corp. is a late-clinical-stage biotechnology company developing rilparencel, an autologous cell therapy for advanced chronic kidney disease and type 2 diabetes. The company manufactures rilparencel by isolating selected renal cells from a patient's own kidney biopsy, expanding them in its manufacturing facility in Winston-Salem, North Carolina, and reinjecting them into the patient's kidneys via a minimally invasive outpatient procedure. The company is currently conducting the Phase 3 PROACT 1 (REGEN-006) trial, which is expected to generate surrogate endpoint data in the second quarter of 2027 and confirmatory endpoint data in the second half of 2029. ProKidney is pre-revenue and depends on additional capital to continue development and potential commercialization of rilparencel. [10-K 2026-03-18]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $376.0K | −$48.46M | −$82.06M | $74.87M | [10-Q 2026-08-10] |
| FY ended Dec 2025 | $893.0K | −$68.99M | −$120.12M | $108.54M | [10-K 2026-03-18] |
| FY ended Dec 2024 | $76.0K | −$61.19M | −$126.35M | $99.12M | [10-K 2026-03-18] |
- Quarterly cash burn
- −$41.03M
- Cash runway Estimate
- ~5.5 months
Capital structure and dilution
- Shelf registration
- S-3 filed 2023-11-22; declared effective 2025-07-07 [S-3 2023-11-22]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-20 | Pereira Brian Jg | sell | 222,948 | $1.42 | [4 2026-08-20] |
| 2026-08-20 | Pereira Brian Jg | sell | 27,052 | $1.42 | [4 2026-08-20] |
| 2026-08-19 | Pereira Brian Jg | sell | 222,949 | $1.44 | [4 2026-08-20] |
| 2026-08-19 | Pereira Brian Jg | sell | 27,051 | $1.44 | [4 2026-08-20] |
| 2026-08-18 | Pereira Brian Jg | sell | 229,338 | $1.37 | [4 2026-08-20] |
| 2026-08-18 | Pereira Brian Jg | sell | 27,826 | $1.37 | [4 2026-08-20] |
| 2026-08-04 | Pereira Brian Jg | other | 81,929 | — | [4 2026-08-06] |
| 2026-08-04 | Pereira Brian Jg | other | 675,235 | — | [4 2026-08-06] |
| 2026-06-12 | Girolamo Todd C | other | 163,857 | — | [4 2026-06-15] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-12 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-10 | 8-K | Results of operations |
| 2026-08-10 | 10-Q | Quarterly report |
| 2026-05-29 | 8-K | Shareholder vote results |
| 2026-05-15 | 8-K | Results of operations; Regulation FD disclosure; Other events |
| 2026-05-15 | 10-Q | Quarterly report |
| 2026-04-30 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-04-17 | DEF 14A | Proxy statement |
| 2026-03-18 | 8-K | Results of operations |
| 2026-03-18 | 10-K | Annual report |
| 2026-02-12 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-02-02 | 8-K | Regulation FD disclosure; Other events |
Alerts for $PROK
Email me when Prokidney Corp. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.